International Journal of Molecular Sciences, 19(7), 1987.
At the highest dose, more participants achieved normal A1c levels than with any other incretin-based therapy tested at the time
It works by: Stimulating insulin secretion in a glucose-dependent manner, which helps lower blood glucose levels in people with type 2 diabetes Suppressing glucagon release from the pancreas, reducing hepatic glucose production Slowing gastric emptying , which prolongs satiety and reduces appetite Acting on appetite centres in the brain , contributing to reduced caloric intake and weight loss Ozempic is administered as a once-weekly subcutaneous injection and has demonstrated significant efficacy in improving glycaemic control and promoting weight reduction in clinical trials
While clinical trials show significant average weight loss with GLP-1 therapy, setting realistic, individualized goals remains key
Research shows that gut bacteriaand the compounds they produce during digestioncan influence GLP-1 secretion in the intestine